This is exactly what I think is coming. Any 2mg has been studied outside of DMC controlled study. Why on earth would you undergo all that to rule an “untested” dose will be used going forwards.
I personally think the cap raise is was more for the immediate need of adding another interim study.
For a wishy washy company they were most wishy washy when discussing this.
AGM 2024 - QUESTIONS, page-53
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |